In its Phase l clinical trial, Palatin Technologies has begun administering PL-8177 to patients to determine its safety and tolerability for the treatment of ulcerative colitis and other inflammatory bowel diseases. Ulcerative colitis is a long-term disease of the large intestine characterized by ulcerations and inflammation that can lead to significant abdominal pain, persistent diarrhea, and...